Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
4D Path›
Analysis
AddedFeb 27, 2023
UpdatedJun 18, 2026
4D Path

4D Path

A statistical physics and tumor biology platform that unveils hidden data for cancer diagnostics.

HQ
Newton, MA, US
Founded
2016
Loading
Overview
Analysis
Compare
Fundraising
Employees
Website

Contents

  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy
  1. 01Products & Services
  2. 02Competitive Strengths
  3. 03Competitive Risks
  4. 04Pricing Strategy

Product Overview

4DPath is a digital pathology company that aims to improve diagnostic accuracy and patient outcomes by leveraging advanced computer vision and machine learning algorithms. The company’s primary product is a software platform that enables pathologists to analyze and interpret tissue samples digitally using high-resolution images captured by a scanner.

The platform uses AI-powered algorithms to assist pathologists in detecting and diagnosing various diseases, including cancer, with greater accuracy and efficiency. By providing pathologists with advanced image analysis tools and automated workflows, 4DPath's platform can help improve the accuracy and speed of diagnoses, ultimately leading to better patient outcomes.

4DPath's product is designed to be compatible with various scanners and can integrate with existing laboratory information management systems (LIMS), making it easier for pathologists to incorporate digital pathology into their existing workflows.

Competitive Advantages

One of 4DPath's main competitive advantages is the strength of its AI-powered image analysis tools. These tools leverage advanced computer vision and machine learning algorithms to assist pathologists in diagnosing diseases with greater accuracy and efficiency. By providing pathologists with more accurate and reliable diagnoses, 4DPath's tools are able to improve patient outcomes.

Another advantage of 4DPath's tools is the overall flexibility and compatibility with various scanners and laboratory information management systems (LIMS). This makes it easier for pathologists to incorporate digital pathology into their existing workflows without completely overhauling their current systems.

Additionally, 4DPath's team includes experienced pathologists and data scientists who have a deep understanding of both the medical and technical aspects of digital pathology. This allows them to develop a platform that is tailored to the specific needs of pathologists and provides them with the tools they need to do their jobs more effectively.

Overall, 4DPath's combination of advanced AI algorithms, compatibility with existing systems, and expertise in pathology and data science gives the company a strong competitive advantage in the digital pathology market.

Competitive Disadvantages

One potential disadvantage for 4DPath is the competition from other digital pathology companies offering AI-powered image analysis platforms. As the digital pathology market grows, more companies are entering the space and developing similar technologies. This could make it challenging for 4DPath to stand out and differentiate itself from its competitors.

Another potential disadvantage is the relatively slow adoption of digital pathology by some healthcare organizations. Some pathologists may prefer to adopt new technologies and workflows, particularly if they are comfortable with traditional methods. This could make it challenging for 4DPath to expand its customer base and reach a wider audience.

Additionally, developing AI-powered algorithms and image analysis platforms requires significant investment in research and development. If 4DPath cannot secure sufficient funding or maintain a strong pipeline of new innovations, the company may struggle to keep up with the competition.

Overall, while 4DPath has several competitive advantages, the company also faces challenges from competitors, slow adoption rates, and the need for continued investment in research and development.

Pricing Strategy

4DPath's pricing strategy is based on a software-as-a-service (SaaS) model, where customers pay a subscription fee for access to the platform. The pricing is tiered, based on the number of users or the volume of images processed.

Additionally, 4DPath offers customized pricing plans to meet the specific needs of different customers, such as academic institutions, hospitals, and research organizations. At the company’s discretion, discounts and/or promotions may be offered to attract new customers or retain existing ones.

4DPath's pricing strategy is relatively competitive with other digital pathology software providers in the market while still providing fair value for their customers. For customers that need additional services, the company also offers white-glove support, such as training and consulting, to differentiate its product stack and provide additional value for high-ticket customers.